Navigation Links
Pneumonia Effectively Treated with Short-Term Antibiotic Course

Recent research has revealed that taking antibiotics for three days rather than the usual concept of seven to 10 days is equally effective in the treatment of common pneumonia // .

According to researchers this could also help to curb the rising problem of antibiotic-resistant bacteria,

Lead researcher Dr. Jan M Prins, an internist in infectious diseases at the Academic Medical Center, in Amsterdam said,’The question is how long you should treat common pneumonia. It turns out that three days is sufficient in children, and we now find the same in adults.’

The research team compared the effectiveness of three days of amoxicillin treatment with eight days of treatment in adults in cases of mild to moderate-severe pneumonia.

119 patients who had improved after three days of treatment with intravenous amoxicillin, and then assigned oral amoxicillin or a placebo for five days were taken as the subjects of the study.v It was found that 93 percent of the patients treated for three day or eight days, got better. Prins said, ‘For patients who responded after three days of antibiotic treatment, you could stop antibiotics and the results were comparable for those treated for eight days.’

The advantage lay in the fact that patients do not have to take in more medication than necessary. ‘In addition, there is a relation between how many antibiotics are used in a community and the rate of resistance among bacteria,’ he said. ‘If you can reduce the use of antibiotics, you can reduce the rate of resistance.’

The results of the research have been published in the June 10 issue of the British Medical Journal.

However Prins has cautioned that all diseases treated with antibiotics cannot become candidates for short-course treatment.

According to Dr. John Paul, from the Royal Sussex County Hospital, in England, and author of an accompanying editorial in the journal, ‘There is a lack of clear evidence to allow clinicians to know the optimal duration of antibiotic therapy for many common infections. He added, ‘We know that some infections do require long-term therapy to prevent relapse. We know for others that short courses of antibiotics are as good as long courses.’

‘This concept is smart,’ said Philip Tierno Jr., director of clinical microbiology and immunology at New York University Medical Center. ‘It eliminates three big problems: The cost to individuals of some of these newer antibiotics, adverse reactions and complications, and the development of resistanc.’


'"/>




Related medicine news :

1. Toxin connected to Flesh-eating Pneumonia in Kids
2. A new Vaccine for Pneumonia
3. The After Effects Of Pneumonia
4. Acid Suppressive Drugs Found To Increase The Risk for Pneumonia
5. Tsunami Survivors Face Pneumonia Threat
6. New Vaccine Found To Be Effective In Reducing Childhood Pneumonia
7. Zinc Effective In Helping Kids Recover From Pneumonia
8. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
9. Pneumonia Claims 30 Lives In Pakistan
10. Pneumonia Vaccine Effective Among Children
11. Five Tribal Children Succumbs to Pneumonia in Orissa
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... ... May 04, 2016 , ... World Patent Marketing , ... a sports invention that aids in the improvement of the grip and swing ... $9 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
(Date:5/4/2016)... Calif. (PRWEB) , ... May 04, 2016 , ... ... for children has donated 100 of its innovative kicking trainers to St. Jude ... , The SOCKIT is a durable, lightweight rubber band designed to teach children ...
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, a ... for its innovative Secure Messaging platform, which includes secure, private messaging, large file ... extends Cirius’s portfolio of patents around innovative features for securing, tracking, and controlling ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... Technology & Business Conference. The conference opened on Tuesday with Frank Luntz, sharing ... on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model solution to ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... disorder management, today announced it has secured $9 million in Series A funding ... investors. The investment will be used by Somnoware to further fulfill its mission ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Multiple Myeloma Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Myeloma epidemiology, Multiple Myeloma market valuations and ...
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
Breaking Medicine Technology: